Month: September 2015

September 28, 2015, by NCI Staff An engineered CAR T cell (center) binding to beads, which cause the T cell to divide. Credit: University of Pennsylvania Perelman School of Medicine, CC BY-NC-SA 2.0 Engineering immune cells to have a decreased ability to bind to their targets on cancer cells doesn’t appear to impair their ability
0 Comments
September 24, 2015, by Lynne Penberthy, M.D. Join the Conversation We welcome your comments and invite you to discuss NCI’s Annual Plan and Budget Proposal with the cancer research community. Visit our social media events page for more information. The following is the first in a series of posts from senior NCI scientists and leaders
0 Comments
September 18, 2015, by NCI Staff NCI’s Clinical Proteomics Tumor Analysis Consortium is focused on studying whether proteomics data can be used to help improve cancer diagnosis, treatment, and prevention. Credit: National Cancer Institute Henry Rodriguez, Ph.D., M.B.A., is director of NCI’s Office of Cancer Clinical Proteomics Research. In this interview, Dr. Rodriguez talks about
0 Comments
September 18, 2015, by NCI Staff Researchers are testing whether using DNA and RNA sequencing can help manage the care of children and young adults with cancer. Credit: iStock Using genomic tools to analyze tumors in children and young adults with difficult-to-treat cancers may help doctors select the most appropriate treatments for some of these
0 Comments
September 17, 2015, by Douglas R. Lowy, M.D. Yesterday, I was proud to submit the NCI Annual Plan and Budget Proposal for Fiscal Year 2017 to President Barack Obama. I believe that the “Bypass Budget,” as it has come to be known, is particularly important to cancer research this year for two reasons. First, this
0 Comments
September 11, 2015, by NCI Staff The FDA has approved a new drug to help prevent nausea and vomiting caused by chemotherapy. Credit: National Cancer Institute. On September 1, the Food and Drug Administration (FDA) approved rolapitant (Varubi®) to prevent delayed phase chemotherapy-induced nausea and vomiting in adult cancer patients. The approval is for the
0 Comments
September 8, 2015, by NCI Staff A computer model of a small molecule drug that inhibits its protein target. Credit: Kevin Gardner, M.D., Ph.D., NCI Center for Cancer Research NCI has awarded grants to five research teams to participate in its Pediatric Preclinical Testing Consortium (PPTC). The PPTC is designed to address an important barrier
0 Comments
September 4, 2015, by NCI Staff In this stage IIIA ovarian cancer, tumors inside both ovaries have spread to the uterus, colon, and surface of the peritoneum. Credit: Terese Winslow Combining intraperitoneal (IP) chemotherapy with intravenous (IV) chemotherapy improves survival in women with advanced ovarian cancer, though its use in clinical practice has been limited,
0 Comments
September 2, 2015, by NCI Staff The outer skin layer (epidermis) includes several cell types, including basal cell keratinocytes, the source cells for BCC. Credit: Terese Winslow On July 24, the Food and Drug Administration (FDA) approved sonidegib (Odomzo®) to treat some patients with basal cell carcinoma (BCC), the most common form of non-melanoma skin
0 Comments
Abstract The assumption underlying current diabetes treatment is that lowering the level of time-averaged glucose concentrations, measured as HbA1c, prevents microvascular complications. However, 89% of variation in risk of retinopathy, microalbuminuria, or albuminuria is due to elements of glycemia not captured by mean HbA1c values. We show that transient exposure to high glucose activates a
0 Comments